About the Team
Join a world-class team at the forefront of AI and biochemistry.
At Genesis Therapeutics, we’re a tight-knit team of proven deep learning researchers, software engineers, and drug discovery pioneers. Our shared mission is nothing short of revolutionary: to forge the next generation of AI foundation models that will unlock groundbreaking therapies for patients with severe diseases.
We don’t just apply machine learning to biology; we are conducting fundamental research at the intersection of machine learning, physics, and computational chemistry, pushing the boundaries of each field. You will work side-by-side with top multidisciplinary researchers to design and build generative foundation models at scale, having access to ample compute and large-scale simulations.
About the Role
This unique role is for a scientist who is passionate about being a catalyst for applying cutting-edge AI to solve real-world drug discovery challenges. You will be the critical bridge between our long-term research and our experimental drug discovery programs. Your mission is to build, evaluate, monitor, and improve our state-of-the-art models directly into active drug programs, leading the charge on model validation, deployment, and analysis to guide the discovery of new medicines.
You will act as both a translator and a strategist, ensuring our research is aimed at the most critical challenges and that our drug hunters can leverage the full power of our industry-leading AI platform. This role requires a deep understanding of cheminformatics, computational chemistry, and experimental techniques, strong data science skills, and a talent for communicating complex ideas to a diverse, multidisciplinary team.
Positions are available at various levels of seniority: Senior, Staff, and Principal.
About Genesis Therapeutics
Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules. Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets.
The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI-focused platform collaborations with major pharmaceutical companies, including most recently Incyte Corporation (Feb 2025) and Gilead Sciences (Sept 2024). We raised a $200M series B in August 2023, and have raised over $300M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures.
Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.